Previous publications from this clinical trial reported that seropositivity for anti-VZV antibodies in MMRV and MMR+V groups was characterized by a persistent and progressive increase of anti-VZV antibody levels from Y1 to Y10.10–12 As previously described, the GMCs at Y10 timepoint were comparable in the Active Control group without censoring of the post-infection data and the MMRV group.11 The gene discussed is MRC1; the disease is infection.